Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).
Michael C. Heinrich
Consultant or Advisory Role - ARIAD
Stock Ownership - MolecularMD
Research Funding - ARIAD
Jonathan A. Fletcher
Consultant or Advisory Role - ARIAD; Novartis; Pfizer
Honoraria - Novartis
Rana Anjum
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Cesar Serrano-Garcia
No relevant relationships to disclose
Sadanand Vodala
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Sebastian Bauer
Honoraria - Bayer; Novartis; Pfizer
Ajia Town
No relevant relationships to disclose
Meijun Zhu
No relevant relationships to disclose
Yaoyu Ning
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Grant Eilers
No relevant relationships to disclose
Diana Griffith
No relevant relationships to disclose
Janice Patterson
No relevant relationships to disclose
Arin McKinley
No relevant relationships to disclose
Frank Y Wang
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Andrew P Garner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD